Tag Archives: Kevin Degeeter

Athenex (ATNX) Gets a Hold Rating from Oppenheimer

In a report released today, Kevin DeGeeter from Oppenheimer maintained a Hold rating on Athenex (ATNX – Research Report). The company’s shares closed last Tuesday at $4.24, close to its 52-week low of $3.66. According to TipRanks.com, DeGeeter is a

Oppenheimer Sticks to Their Hold Rating for Vericel (VCEL)

Oppenheimer analyst Kevin DeGeeter reiterated a Hold rating on Vericel (VCEL – Research Report) today. The company’s shares closed last Tuesday at $57.77. According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 43.9% and a 48.9%

Mediwound (MDWD) Receives a New Rating from a Top Analyst

Oppenheimer analyst Kevin DeGeeter assigned a Buy rating to Mediwound (MDWD – Research Report) today and set a price target of $7.00. The company’s shares closed last Wednesday at $4.00. According to TipRanks.com, DeGeeter is a top 100 analyst with

Orchard Therapeutics (ORTX) Receives a Buy from Oppenheimer

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Orchard Therapeutics (ORTX – Research Report) yesterday and set a price target of $17.00. The company’s shares closed last Friday at $5.45. According to TipRanks.com, DeGeeter is a 5-star analyst with

Oppenheimer Remains a Buy on DermTech (DMTK)

In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on DermTech (DMTK – Research Report), with a price target of $58.00. The company’s shares closed last Thursday at $29.14. According to TipRanks.com, DeGeeter is a 5-star

Oppenheimer Releases a Buy Rating on Cellectar Biosciences (CLRB)

In a report released today, Kevin DeGeeter from Oppenheimer assigned a Buy rating to Cellectar Biosciences (CLRB – Research Report), with a price target of $5.50. The company’s shares closed last Friday at $1.59. According to TipRanks.com, DeGeeter is a